Indaptus Therapeutics, Inc.
INDPHealthcare|Biotechnology|US
$3.32
+0.16 (+5.06%)
DCF Value
$8.29
Tangible Book / Share
$0.10
Cash / Share
$0.10
Clinical Trials (1)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05651022 Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors | Solid Tumor, Adult, HCC - Hepatocellular Carcinoma | P1P2 | Active | 120 | Open-label | Decoy20, Tislelizumab |